Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two Part, Non-randomized, Open Label Study Designed to Assess the Pharmacokinetics of GSK2982772 Following Administration of Modified Release Formulations in Capsule Relative to an Immediate Release Reference Tablet Formulation (Part A) and the Pharmacokinetics of Escalating, Repeat Doses of a Selected Modified Release Prototype (Part B) in Healthy Subjects

Trial Profile

A Two Part, Non-randomized, Open Label Study Designed to Assess the Pharmacokinetics of GSK2982772 Following Administration of Modified Release Formulations in Capsule Relative to an Immediate Release Reference Tablet Formulation (Part A) and the Pharmacokinetics of Escalating, Repeat Doses of a Selected Modified Release Prototype (Part B) in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs GSK 2982772 (Primary) ; GSK 2982772 (Primary)
  • Indications Inflammatory bowel diseases; Plaque psoriasis; Rheumatoid arthritis; Ulcerative colitis
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Jan 2019 Status changed from recruiting to completed.
    • 11 Oct 2018 Planned End Date changed from 31 Oct 2018 to 13 Nov 2018.
    • 11 Oct 2018 Planned primary completion date changed from 31 Oct 2018 to 13 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top